{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T21:46:08Z","timestamp":1790027168599,"version":"4.0.1"},"reference-count":77,"publisher":"National Institute for Health and Care Research","issue":"47","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/non-commercial-government-licence\/non-commercial-government-licence.htm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["11\/129\/187"],"award-info":[{"award-number":["11\/129\/187"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalslibrary.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"\n Background<\/jats:title>\n The comparative efficacy, and cost-effectiveness, of imiquimod or podophyllotoxin cream, either alone or in combination with the quadrivalent HPV vaccine (Gardasil\u00ae<\/jats:sup>, Merck Sharp & Dohme Corp., Merck & Co., Inc., Whitehouse Station, NJ, USA) in the treatment and prevention of recurrence of anogenital warts is not known.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n The objective was to compare the efficacy of imiquimod and podophyllotoxin creams to treat anogenital warts and to assess whether or not the addition of quadrivalent human papillomavirus vaccine increases wart clearance or prevention of recurrence.<\/jats:p>\n <\/jats:sec>\n \n Design<\/jats:title>\n A randomised, controlled, multicentre, partially blinded factorial trial. Participants were randomised equally to four groups, combining either topical treatment with quadrivalent human papillomavirus vaccine or placebo. Randomisation was stratified by gender, a history of previous warts and human immunodeficiency virus status. There was an accompanying economic evaluation, conducted from the provider perspective over the trial duration.<\/jats:p>\n <\/jats:sec>\n \n Setting<\/jats:title>\n The setting was 22 sexual health clinics in England and Wales.<\/jats:p>\n <\/jats:sec>\n \n Participants<\/jats:title>\n Participants were patients with a first or repeat episode of anogenital warts who had not been treated in the previous 3 months and had not previously received quadrivalent human papillomavirus vaccine.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Participants were randomised to 5% imiquimod cream (Aldara\u00ae<\/jats:sup>; Meda Pharmaceuticals, Takeley, UK) for up to 16 weeks or 0.15% podophyllotoxin cream (Warticon\u00ae<\/jats:sup>; GlaxoSmithKlein plc, Brentford, UK) for 4 weeks, which was extended to up to 16 weeks if warts persisted. Participants were simultaneously randomised to quadrivalent human papillomavirus vaccine (Gardasil) or saline control at 0, 8 and 24 weeks. Cryotherapy was permitted after week 4 at the discretion of the investigator.<\/jats:p>\n <\/jats:sec>\n \n Main outcome measures<\/jats:title>\n The main outcome measures were a combined primary outcome of wart clearance at week 16 and remaining wart free at week 48. Efficacy analysis was by logistic regression with multiple imputation for missing follow-up values; economic evaluation considered the costs per quality-adjusted life-year.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 503 participants were enrolled and attended at least one follow-up visit. The mean age was 31 years, 66% of participants were male (24% of males were men who have sex with men), 50% had a previous history of warts and 2% were living with human immunodeficiency virus. For the primary outcome, the adjusted odds ratio for imiquimod cream versus podophyllotoxin cream was 0.81 (95% confidence interval 0.54 to 1.23), and for quadrivalent human papillomavirus vaccine versus placebo, the adjusted odds ratio was 1.46 (95% confidence interval 0.97 to 2.20). For the components of the primary outcome, the adjusted odds ratio for wart free at week 16 for imiquimod versus podophyllotoxin was 0.77 (95% confidence interval 0.52 to 1.14) and for quadrivalent human papillomavirus vaccine versus placebo was 1.30 (95% confidence interval 0.89 to 1.91). The adjusted odds ratio for remaining wart free at 48 weeks (in those who were wart free at week 16) for imiquimod versus podophyllotoxin was 0.98 (95% confidence interval 0.54 to 1.78) and for quadrivalent human papillomavirus vaccine versus placebo was 1.39 (95% confidence interval 0.73 to 2.63). Podophyllotoxin plus quadrivalent human papillomavirus vaccine had inconclusive cost-effectiveness compared with podophyllotoxin alone.<\/jats:p>\n <\/jats:sec>\n \n Limitations<\/jats:title>\n Hepatitis A vaccine as control was replaced by a saline placebo in a non-identical syringe, administered by someone outside the research team, for logistical reasons. Sample size was reduced from 1000 to 500 because of slow recruitment and other delays.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n A benefit of the vaccine was not demonstrated in this trial. The odds of clearance at week 16 and remaining clear at week 48 were 46% higher with vaccine, and consistent effects were seen for both wart clearance and recurrence separately, but these differences were not statistically significant. Imiquimod and podophyllotoxin creams had similar efficacy for wart clearance, but with a wide confidence interval. The trial results do not support earlier evidence of a lower recurrence with use of imiquimod than with use of podophyllotoxin. Podophyllotoxin without quadrivalent human papillomavirus vaccine is the most cost-effective strategy at the current vaccine list price. A further larger trial is needed to definitively investigate the effect of the vaccine; studies of the immune response in vaccine recipients are needed to investigate the mechanism of action.<\/jats:p>\n <\/jats:sec>\n \n Trial registration<\/jats:title>\n Current Controlled Trials. Current Controlled Trials ISRCTN32729817 and EudraCT 2013-002951-14.<\/jats:p>\n <\/jats:sec>\n \n Funding<\/jats:title>\n This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment<\/jats:italic>; Vol. 24, No. 47. See the NIHR Journals Library website for further project information.<\/jats:p>\n <\/jats:sec>","DOI":"10.3310\/hta24470","type":"journal-article","created":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T11:52:09Z","timestamp":1601034729000},"page":"1-86","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":33,"title":["Imiquimod versus podophyllotoxin, with and without human papillomavirus vaccine, for anogenital warts: the HIPvac factorial RCT"],"prefix":"10.3310","volume":"24","clinical-trial-number":[{"clinical-trial-number":"isrctn16738765","registry":"10.18810\/isrctn","type":"results"},{"clinical-trial-number":"2013-002951-14","registry":"10.18810\/euctr","type":"results"},{"clinical-trial-number":"isrctn32729817","registry":"10.18810\/isrctn","type":"results"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9572-193X","authenticated-orcid":true,"given":"Richard","family":"Gilson","sequence":"first","affiliation":[{"name":"University College London Centre for Clinical Research in Infection and Sexual Health, Institute for Global Health, University College London, London, UK"},{"name":"Mortimer Market Centre, Central and North West London NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7417-8440","authenticated-orcid":true,"given":"Diarmuid","family":"Nugent","sequence":"additional","affiliation":[{"name":"University College London Centre for Clinical Research in Infection and Sexual Health, Institute for Global Health, University College London, London, UK"},{"name":"Mortimer Market Centre, Central and North West London NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2358-4497","authenticated-orcid":true,"given":"Kate","family":"Bennett","sequence":"additional","affiliation":[{"name":"Comprehensive Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9796-4970","authenticated-orcid":true,"given":"Caroline J","family":"Dor\u00e9","sequence":"additional","affiliation":[{"name":"Comprehensive Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6418-0854","authenticated-orcid":true,"given":"Macey L","family":"Murray","sequence":"additional","affiliation":[{"name":"Comprehensive Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0337-5011","authenticated-orcid":true,"given":"Jade","family":"Meadows","sequence":"additional","affiliation":[{"name":"Comprehensive Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3016-2986","authenticated-orcid":true,"given":"Lewis J","family":"Haddow","sequence":"additional","affiliation":[{"name":"University College London Centre for Clinical Research in Infection and Sexual Health, Institute for Global Health, University College London, London, UK"},{"name":"Mortimer Market Centre, Central and North West London NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9250-2638","authenticated-orcid":true,"given":"Charles","family":"Lacey","sequence":"additional","affiliation":[{"name":"Centre for Immunology and Infection, Hull York Medical School, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5641-1931","authenticated-orcid":true,"given":"Frank","family":"Sandmann","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK"},{"name":"Statistics, Modelling and Economics Department, Public Health England, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6658-8255","authenticated-orcid":true,"given":"Mark","family":"Jit","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK"},{"name":"Statistics, Modelling and Economics Department, Public Health England, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0361-3174","authenticated-orcid":true,"given":"Kate","family":"Soldan","sequence":"additional","affiliation":[{"name":"Statistics, Modelling and Economics Department, Public Health England, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1064-3187","authenticated-orcid":true,"given":"Michelle","family":"Tetlow","sequence":"additional","affiliation":[{"name":"Comprehensive Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4420-713X","authenticated-orcid":true,"given":"Emilia","family":"Caverly","sequence":"additional","affiliation":[{"name":"Comprehensive Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9123-7657","authenticated-orcid":true,"given":"Mayura","family":"Nathan","sequence":"additional","affiliation":[{"name":"Homerton Anogenital Neoplasia Service, Homerton University Hospital NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8968-5963","authenticated-orcid":true,"given":"Andrew J","family":"Copas","sequence":"additional","affiliation":[{"name":"Comprehensive Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, UK"},{"name":"Medical Research Council Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2020,9]]},"reference":[{"key":"key20200921153723849_ref1-bib1","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1002\/jmv.22111","article-title":"Analyses of human papillomavirus genotypes and viral loads in anogenital warts","volume":"83","author":"Ball","year":"2011","journal-title":"J Med Virol"},{"key":"key20200921153723849_ref1-bib2","unstructured":"Public Health England (PHE). Sexually Transmitted Infections (STIs): Annual Data Tables. Table 1: STI Diagnoses and Rates in England by Gender, 2009 to 2018. London: PHE; 2019. URL: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/805903\/2018_Table_1_STI_diagnoses_and_rates_in_England_by_gender.ods (accessed 26 October 2018)."},{"key":"key20200921153723849_ref1-bib3","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1136\/sti.2010.048421","article-title":"Genital warts and cost of care in England","volume":"87","author":"Desai","year":"2011","journal-title":"Sex Transm Infect"},{"key":"key20200921153723849_ref1-bib4","volume-title":"UK National Guidelines on the Management of Anogenital Warts 2015","author":"British Association for Sexual Health and HIV (BASHH)"},{"key":"key20200921153723849_ref1-bib5","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1111\/j.1468-3083.2012.04493.x","article-title":"2012 European guideline for the management of anogenital warts","volume":"27","author":"Lacey","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key20200921153723849_ref1-bib6","volume-title":"Sexually Transmitted Diseases Treatment Guidelines, 2015","author":"Centers for Disease Control and Prevention (CDC)"},{"key":"key20200921153723849_ref1-bib7","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1136\/sti.64.4.263","article-title":"Podophyllotoxin 0.5% v podophyllin 20% to treat penile warts","volume":"64","author":"Edwards","year":"1988","journal-title":"Genitourin Med"},{"key":"key20200921153723849_ref1-bib8","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/S0140-6736(89)92282-4","article-title":"Patient-applied podofilox for treatment of genital warts","volume":"1","author":"Beutner","year":"1989","journal-title":"Lancet"},{"key":"key20200921153723849_ref1-bib9","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3109\/09546639009086712","article-title":"Clinical efficacy of Condyline (0.5% podophyllotoxin) solution and cream versus podophyllin in the treatment of external condylomata acuminata","volume":"1","author":"Mazurkiewicz","year":"1990","journal-title":"J Dermatolog Treat"},{"key":"key20200921153723849_ref1-bib10","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/0002-9343(90)90424-C","article-title":"Double-blind randomized clinical trial of self-administered podofilox solution versus vehicle in the treatment of genital warts","volume":"88","author":"Kirby","year":"1990","journal-title":"Am J Med"},{"key":"key20200921153723849_ref1-bib11","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1136\/sti.70.2.105","article-title":"Self-treatment using 0.25%\u20130.50% podophyllotoxin-ethanol solutions against penile condylomata acuminata: a placebo-controlled comparative study","volume":"70","author":"von Krogh","year":"1994","journal-title":"Genitourin Med"},{"key":"key20200921153723849_ref1-bib12","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1136\/sti.71.6.387","article-title":"Topical treatment of genital warts in men, an open study of podophyllotoxin cream compared with solution","volume":"71","author":"Strand","year":"1995","journal-title":"Genitourin Med"},{"key":"key20200921153723849_ref1-bib13","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1258\/0956462961918400","article-title":"Topical treatment of venereal warts: a comparative open study of podophyllotoxin cream versus solution","volume":"7","author":"Claesson","year":"1996","journal-title":"Int J STD AIDS"},{"key":"key20200921153723849_ref1-bib14","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1136\/sti.79.4.270","article-title":"Randomised controlled trial and economic evaluation of podophyllotoxin solution, podophyllotoxin cream, and podophyllin in the treatment of genital warts","volume":"79","author":"Lacey","year":"2003","journal-title":"Sex Transm Infect"},{"key":"key20200921153723849_ref1-bib15","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/OLQ.0b013e3181f68ebb","article-title":"Efficacy and safety of imiquimod versus podophyllotoxin in the treatment of anogenital warts","volume":"38","author":"Komericki","year":"2011","journal-title":"Sex Transm Dis"},{"key":"key20200921153723849_ref1-bib16","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1136\/sextrans-2016-052768","article-title":"Self-administered interventions for anogenital warts in immunocompetent patients: a systematic review and meta-analysis","volume":"93","author":"Werner","year":"2017","journal-title":"Sex Transm Infect"},{"key":"key20200921153723849_ref1-bib17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1471-2334-1-3","article-title":"Imiquimod for the treatment of genital warts: a quantitative systematic review","volume":"1","author":"Moore","year":"2001","journal-title":"BMC Infect Dis"},{"key":"key20200921153723849_ref1-bib18","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0166-3542(99)00033-9","article-title":"Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%","volume":"43","author":"Arany","year":"1999","journal-title":"Antiviral Res"},{"key":"key20200921153723849_ref1-bib19","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0190-9622(98)70243-9","article-title":"Treatment of genital warts with an immune-response modifier (imiquimod)","volume":"38","author":"Beutner","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"key20200921153723849_ref1-bib20","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1128\/AAC.42.4.789","article-title":"Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts","volume":"42","author":"Beutner","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"key20200921153723849_ref1-bib21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/archderm.134.1.25","article-title":"Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus","volume":"134","author":"Edwards","year":"1998","journal-title":"Arch Dermatol"},{"key":"key20200921153723849_ref1-bib22","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1097\/00007435-200104000-00007","article-title":"Treatment of external genital warts in men using 5% imiquimod cream applied three times a week, once daily, twice daily, or three times a day","volume":"28","author":"Fife","year":"2001","journal-title":"Sex Transm Dis"},{"key":"key20200921153723849_ref1-bib23","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1111\/j.1346-8138.2004.tb00568.x","article-title":"Topical imiquimod 5% cream in external anogenital warts: a randomized, double-blind, placebo-controlled study","volume":"31","author":"Arican","year":"2004","journal-title":"J Dermatol"},{"key":"key20200921153723849_ref1-bib24","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1258\/095646206777689161","article-title":"An open-label phase II pilot study investigating the optimal duration of imiquimod 5% cream for the treatment of external genital warts in women","volume":"17","author":"Garland","year":"2006","journal-title":"Int J STD AIDS"},{"key":"key20200921153723849_ref1-bib25","first-page":"642","article-title":"Randomized, comparative trial on the sustained efficacy of topical imiquimod 5% cream versus conventional ablative methods in external anogenital warts","volume":"16","author":"Sch\u00f6fer","year":"2006","journal-title":"Eur J Dermatol"},{"key":"key20200921153723849_ref1-bib26","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010389.pub2","article-title":"Imiquimod for anogenital warts in non-immunocompromised adults","volume":"11","author":"Grillo-Ardila","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"key20200921153723849_ref1-bib27","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1001\/archdermatol.2010.71","article-title":"Recalcitrant cutaneous warts treated with recombinant quadrivalent human papillomavirus vaccine (types 6, 11, 16, and 18) in a developmentally delayed, 31-year-old white man","volume":"146","author":"Venugopal","year":"2010","journal-title":"Arch Dermatol"},{"key":"key20200921153723849_ref1-bib28","doi-asserted-by":"publisher","first-page":"e130","DOI":"10.1016\/j.jaad.2010.12.032","article-title":"Condyloma accuminatum treated with recombinant quadrivalent human papillomavirus vaccine (types 6, 11, 16, 18)","volume":"64","author":"Lee","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"key20200921153723849_ref1-bib29","doi-asserted-by":"publisher","first-page":"696","DOI":"10.4161\/hv.5.10.9515","article-title":"Evaluation of quadrivalent HPV 6\/11\/16\/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection","volume":"5","author":"Olsson","year":"2009","journal-title":"Hum Vaccin"},{"key":"key20200921153723849_ref1-bib30","doi-asserted-by":"publisher","first-page":"e1401","DOI":"10.1136\/bmj.e1401","article-title":"Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data","volume":"344","author":"Joura","year":"2012","journal-title":"BMJ"},{"key":"key20200921153723849_ref1-bib31","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1002\/ijc.11474","article-title":"Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomized clinical trial","volume":"107","author":"Hogewoning","year":"2003","journal-title":"Int J Cancer"},{"key":"key20200921153723849_ref1-bib32","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1038\/sj.bjc.6602524","article-title":"HPV type concordance in sexual couples determines the effect of condoms on regression of flat penile lesions","volume":"92","author":"Bleeker","year":"2005","journal-title":"Br J Cancer"},{"key":"key20200921153723849_ref1-bib33","volume-title":"Laryngeal Papillomatosis: Immunological and Clinical Responses to HPV and Vaccination","author":"Fromm"},{"key":"key20200921153723849_ref1-bib34","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1586\/erv.12.20","article-title":"A prophylactic quadrivalent vaccine for the prevention of infection and disease related to HPV-6, -11, -16 and -18","volume":"11","author":"Goldstone","year":"2012","journal-title":"Expert Rev Vaccines"},{"key":"key20200921153723849_ref1-bib35","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1099\/0022-1317-75-8-2075","article-title":"Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera","volume":"75","author":"Rose","year":"1994","journal-title":"J Gen Virol"},{"key":"key20200921153723849_ref1-bib36","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1136\/sextrans-2011-050073","article-title":"The impact of genital warts: loss of quality of life and cost of treatment in eight sexual health clinics in the UK","volume":"87","author":"Woodhall","year":"2011","journal-title":"Sex Transm Infect"},{"key":"key20200921153723849_ref1-bib37","doi-asserted-by":"publisher","first-page":"d5775","DOI":"10.1136\/bmj.d5775","article-title":"Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model","volume":"343","author":"Jit","year":"2011","journal-title":"BMJ"},{"key":"key20200921153723849_ref1-bib38","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12874-018-0581-z","article-title":"Human papillomavirus infection: protocol for a randomised controlled trial of imiquimod cream (5%) versus podophyllotoxin cream (0.15%), in combination with quadrivalent human papillomavirus or control vaccination in the treatment and prevention of recurrence of anogenital warts (HIPvac trial)","volume":"18","author":"Murray","year":"2018","journal-title":"BMC Med Res Methodol"},{"key":"key20200921153723849_ref1-bib39","doi-asserted-by":"publisher","first-page":"s2","DOI":"10.1111\/hiv.12424","article-title":"British HIV Association Guidelines on the Use of Vaccines in HIV-Positive Adults 2015","volume":"17","author":"Geretti","year":"2016","journal-title":"HIV Med"},{"key":"key20200921153723849_ref1-bib40","doi-asserted-by":"publisher","first-page":"3668","DOI":"10.1016\/j.vaccine.2013.06.012","article-title":"Factors associated with the immune response to hepatitis A vaccination in HIV-infected patients in the era of highly active antiretroviral therapy","volume":"31","author":"Mena","year":"2013","journal-title":"Vaccine"},{"key":"key20200921153723849_ref1-bib41","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1097\/QAD.0b013e32836381cc","article-title":"Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM","volume":"27","author":"Martin","year":"2013","journal-title":"AIDS"},{"key":"key20200921153723849_ref1-bib42","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/sim.4067","article-title":"Multiple imputation using chained equations: issues and guidance for practice","volume":"30","author":"White","year":"2011","journal-title":"Stat Med"},{"key":"key20200921153723849_ref1-bib43","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jval.2015.02.001","article-title":"Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report","volume":"18","author":"Ramsey","year":"2015","journal-title":"Value Health"},{"key":"key20200921153723849_ref1-bib44","unstructured":"National Institute for Health and Care Excellence (NICE). Guide to the Methods of Technology Appraisal. London: NICE; 2013."},{"key":"key20200921153723849_ref1-bib45","unstructured":"Joint Committee on Vaccination and Immunisation. Code of Practice June 2013. London: Public Health England; 2013."},{"key":"key20200921153723849_ref1-bib46","volume-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"2015"},{"key":"key20200921153723849_ref1-bib47","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S0167-6296(98)00039-3","article-title":"The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies","volume":"18","author":"Claxton","year":"1999","journal-title":"J Health Econ"},{"key":"key20200921153723849_ref1-bib48","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1017\/s0266462300011442","article-title":"A note on confidence intervals in cost-effectiveness analysis","volume":"14","author":"Tambour","year":"1998","journal-title":"Int J Technol Assess Health Care"},{"key":"key20200921153723849_ref1-bib49","volume-title":"Drug Tariff 2018","author":"NHS Business Services Authority"},{"key":"key20200921153723849_ref1-bib50","unstructured":"Joint Formulary Committee. British National Formulary. 75 ed. London: BMJ Group and Pharmaceutical Press; 2018."},{"key":"key20200921153723849_ref1-bib51","volume-title":"Consumer Price Indices (CPIs) \u2013 Complete Database: Consumer Prices \u2013 Annual Inflation, All Items Non-Food Non-Energy","author":"Organisation for Economic Co-operation and Development (OECD)"},{"key":"key20200921153723849_ref1-bib52","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"key":"key20200921153723849_ref1-bib53","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/hec.3564","article-title":"Valuing health-related quality of life: an EQ-5D-5L value set for England","volume":"27","author":"Devlin","year":"2018","journal-title":"Health Econ"},{"key":"key20200921153723849_ref1-bib54","volume-title":"Position Statement on Use of the EQ-5D-5L Value Set for England (Updated October 2019)","author":"National Institute for Health and Care Excellence"},{"key":"key20200921153723849_ref1-bib55","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","article-title":"Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets","volume":"15","author":"van Hout","year":"2012","journal-title":"Value Health"},{"key":"key20200921153723849_ref1-bib56","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/hec.944","article-title":"Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility","volume":"14","author":"Manca","year":"2005","journal-title":"Health Econ"},{"key":"key20200921153723849_ref1-bib57","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s40273-018-0650-5","article-title":"Sensitivity analysis for not-at-random missing data in trial-based cost-effectiveness analysis: a tutorial","volume":"36","author":"Leurent","year":"2018","journal-title":"PharmacoEconomics"},{"key":"key20200921153723849_ref1-bib58","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1111\/j.1524-4733.2008.00358.x","article-title":"Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI)","volume":"11","author":"Barton","year":"2008","journal-title":"Value Health"},{"key":"key20200921153723849_ref1-bib59","volume-title":"2018 European Guideline for the Management of Anogenital Warts (Draft Version for Consultation)","author":"Gilson"},{"key":"key20200921153723849_ref1-bib60","volume-title":"Warticon Cream","author":"Electronic medicines compendium (emc)"},{"key":"key20200921153723849_ref1-bib61","volume-title":"Aldara 5% Cream","author":"Electronic medicines compendium (emc)"},{"key":"key20200921153723849_ref1-bib62","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s40273-018-0628-3","article-title":"Comparing the UK EQ-5D-3L and English EQ-5D-5L value sets","volume":"36","author":"Mulhern","year":"2018","journal-title":"PharmacoEconomics"},{"key":"key20200921153723849_ref1-bib63","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jval.2017.09.004","article-title":"EQ-5D-5L versus EQ-5D-3L: the impact on cost effectiveness in the United Kingdom","volume":"21","author":"Hernandez Alava","year":"2018","journal-title":"Value Health"},{"key":"key20200921153723849_ref1-bib64","doi-asserted-by":"publisher","first-page":"5087","DOI":"10.1016\/j.vaccine.2014.06.038","article-title":"Efficacy of the HPV-16\/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16\/18 vaccine trial","volume":"32","author":"Hildesheim","year":"2014","journal-title":"Vaccine"},{"key":"key20200921153723849_ref1-bib65","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","article-title":"Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial","volume":"369","author":"Paavonen","year":"2007","journal-title":"Lancet"},{"key":"key20200921153723849_ref1-bib66","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/hec.766","article-title":"Missing .\u2009.\u2009. presumed at random: cost-analysis of incomplete data","volume":"12","author":"Briggs","year":"2003","journal-title":"Health Econ"},{"key":"key20200921153723849_ref1-bib67","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s40273-018-0622-9","article-title":"3L, 5L, What the L? A NICE conundrum","volume":"36","author":"Devlin","year":"2018","journal-title":"PharmacoEconomics"},{"key":"key20200921153723849_ref1-bib68","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","author":"Garland","year":"2007","journal-title":"N Engl J Med"},{"key":"key20200921153723849_ref1-bib69","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1056\/NEJMoa061741","article-title":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions","volume":"356","author":"Future II Study Group","year":"2007","journal-title":"N Engl J Med"},{"key":"key20200921153723849_ref1-bib70","volume-title":"A Randomized, Placebo-controlled, Phase IIIb HPV Vaccination Trial with Gardasil\u00ae in Patients with Recurrent Condylomata Acuminata","author":"EU Clinical Trials Register"},{"key":"key20200921153723849_ref1-bib71","volume-title":"Efficacy of Quadrivalent HPV Vaccine to Prevent Relapses of Genital Warts After Initial Therapeutic Response (CONDYVAC)","author":"ClinicalTrials.gov"},{"key":"key20200921153723849_ref1-bib72","first-page":"1","article-title":"Cancer chemoprevention by tea polyphenols","volume":"24","author":"Lin","year":"2000","journal-title":"Proc Natl Sci Counc Repub China B"},{"key":"key20200921153723849_ref1-bib73","doi-asserted-by":"publisher","first-page":"364","DOI":"10.3109\/08923973.2014.953637","article-title":"Immunomodulatory effects of EGCG fraction of green tea extract in innate and adaptive immunity via T regulatory cells in murine model","volume":"36","author":"Kuo","year":"2014","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"key20200921153723849_ref1-bib74","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1111\/j.1468-3083.2007.02441.x","article-title":"A randomized, double-blind, four-arm parallel-group, placebo-controlled Phase II\/III study to investigate the clinical efficacy of two galenic formulations of Polyphenon E in the treatment of external genital warts","volume":"21","author":"Gross","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key20200921153723849_ref1-bib75","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1111\/j.1365-2133.2008.08520.x","article-title":"Topical Polyphenon E in the treatment of external genital and perianal warts: a randomized controlled trial","volume":"158","author":"Stockfleth","year":"2008","journal-title":"Br J Dermatol"},{"key":"key20200921153723849_ref1-bib76","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1097\/AOG.0b013e3181719b60","article-title":"Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts: a randomized controlled trial","volume":"111","author":"Tatti","year":"2008","journal-title":"Obstet Gynecol"},{"key":"key20200921153723849_ref1-bib77","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/j.1468-3083.2010.03796.x","article-title":"Efficacy, safety and tolerability of green tea catechins in the treatment of external anogenital warts: a systematic review and meta-analysis","volume":"25","author":"Tzellos","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2034023","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta24470\/hta24470.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2034023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T15:36:43Z","timestamp":1692113803000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/hta24470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":77,"journal-issue":{"issue":"47","published-online":{"date-parts":[[2020,9]]}},"alternative-id":["10.3310\/hta24470"],"URL":"https:\/\/doi.org\/10.3310\/hta24470","relation":{},"ISSN":["1366-5278","2046-4924"],"issn-type":[{"value":"1366-5278","type":"print"},{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"},{"value":"9-2013","name":"contractual_start_date","label":"Contractual start date","group":{"name":"article_history","label":"Article History"}},{"value":"12-2018","name":"editorial_review_begun","label":"Editorial review begun","group":{"name":"article_history","label":"Article History"}},{"value":"9-2019","name":"accepted_for_publication","label":"Accepted for publication","group":{"name":"article_history","label":"Article History"}}]}}